Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

Trading on the OTCQB Venture Market in the US

York, (UK) and Madison, WI (US) 10 March 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that trading in the Company's ordinary shares will begin next month on the OTCQB Venture Market ("OTCQB") in the United States, under the ticker symbol "ABDXF".

By trading on the OTCQB, Abingdon Health shares will be available to trade in US dollars by investors during US working hours. Being available on the OTCQB platform has the potential to increase liquidity in Abingdon Health shares on AIM by attracting a larger universe of investors. The OTCQB is designed for entrepreneurial and development stage US and international companies.

Abingdon Health announced the second phase of a facility expansion at its Madison, Wisconsin (US) site in September 2025. Having raised the proceeds to support and expedite this growth in October 2025, this build-out will complement Abingdon Health's UK operations to allow manufacturing for customers under the same conditions and quality management system in either the USA, the UK, or both. The US expansion will provide customers with unrivalled geographic optionality during a period of tariff and supply chain uncertainty, and provides US customers with the knowledge that their products "developed in the USA" by the Company's highly skilled CDMO team can also be "made in the USA".

Foreign Private Issuers, such as Abingdon Health, that trade on the OTCQB are exempt under the US Exchange Act Rule 12g3-2(b) from SEC reporting if they make whatever information is required by their home market regulator publicly available to US investors in English. Abingdon Health will therefore face no extra reporting obligations and incur minimal ongoing costs as a result of the Company's Ordinary Shares being traded on the OTCQB. 

Abingdon Health's Ordinary Shares will continue to trade on the London Stock Exchange's AIM Market under the symbol "ABDX".

Chris Hand, Executive Chairman, commented: "Having seen our physical footprint and customer portfolio grow in the US following the establishment and expansion of our facility in Madison, Wisconsin, we believe that Abingdon Health is becoming increasingly relevant to US investors. This OTCQB launch will not only make our shares accessible to investors in the US - the largest lateral flow and med-tech market in the world with significant areas of unmet need - but also increase liquidity and benefit our investors on AIM. We look forward to meeting and engaging with our new US investors soon."

Any shareholders wishing to keep up to date with Abingdon Health news, please email [email protected]

Enquiries:

About Abingdon Health

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.   

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success. 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK.  Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.   The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities. 

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.